Gilead (GILD) announced topline results from the Phase 3 ASCENT-03 study of Trodelvy. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful ...

Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration ...

HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

(DIS), Gilead Sciences, Inc. (GILD) and Eaton Corp. plc (ETN), as well as a micro-cap stock Maui Land & Pineapple Co., Inc. (MLP). The Zacks microcap research is unique as our research content on ...

Drugmaker Gilead is adding to its promised investments in the U.S., vowing to spend another $11B on top of the $21B it has already committed to research, development and manufacturing.

As one of America's Greenest Companies, we're always working to ensure our medicines are delivered in ways that safeguard the planet. Gilead Sciences Gilead Sciences, Inc. is a research-based ...

Results from an interim analysis of the Phase III ASSURE trial found that Gilead’s Livdelzi (seladelpar) demonstrated sustained efficacy and a favorable safety profile in patients with primary biliary ...

Analysts expect Hookipa Pharma to post earnings of ($0.61) per share and revenue of $3.38 million for the quarter. Hookipa Pharma Trading Up 15.6 % HOOK opened at $1.48 on Wednesday.

Investing.com - Hookipa Pharma (NASDAQ: HOOK) reported first quarter EPS of $-0.170, $0.04 better than the analyst estimate of ...

Adapted from the seminal 1985 novel by Margaret Atwood, The Handmaid’s Tale tells the story of life in the dystopia of Gilead, a totalitarian society in what was formerly the United States.